Literature DB >> 26458803

Particle-based platforms for malaria vaccines.

Yimin Wu1, David L Narum2, Sylvain Fleury3, Gary Jennings4, Anjali Yadava5.   

Abstract

Recombinant subunit vaccines in general are poor immunogens likely due to the small size of peptides and proteins, combined with the lack or reduced presentation of repetitive motifs and missing complementary signal(s) for optimal triggering of the immune response. Therefore, recombinant subunit vaccines require enhancement by vaccine delivery vehicles in order to attain adequate protective immunity. Particle-based delivery platforms, including particulate antigens and particulate adjuvants, are promising delivery vehicles for modifying the way in which immunogens are presented to both the innate and adaptive immune systems. These particle delivery platforms can also co-deliver non-specific immunostimodulators as additional adjuvants. This paper reviews efforts and advances of the Particle-based delivery platforms in development of vaccines against malaria, a disease that claims over 600,000 lives per year, most of them are children under 5 years of age in sub-Sahara Africa.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvant; Delivery; Malaria; Particle; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 26458803      PMCID: PMC4688205          DOI: 10.1016/j.vaccine.2015.09.097

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  68 in total

1.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.

Authors:  Kent E Kester; James F Cummings; Opokua Ofori-Anyinam; Christian F Ockenhouse; Urszula Krzych; Philippe Moris; Robert Schwenk; Robin A Nielsen; Zufan Debebe; Evgeny Pinelis; Laure Juompan; Jack Williams; Megan Dowler; V Ann Stewart; Robert A Wirtz; Marie-Claude Dubois; Marc Lievens; Joe Cohen; W Ripley Ballou; D Gray Heppner
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

2.  Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.

Authors:  Joanne M Lumsden; Saule Nurmukhambetova; Jennifer H Klein; Jetsumon Sattabongkot; Jason W Bennett; Sylvie Bertholet; Christopher B Fox; Steven G Reed; Christian F Ockenhouse; Randall F Howard; Mark E Polhemus; Anjali Yadava
Journal:  Vaccine       Date:  2012-03-13       Impact factor: 3.641

Review 3.  ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases.

Authors:  Adriana Baz Morelli; Dorit Becher; Sandra Koernig; Anabel Silva; Debbie Drane; Eugene Maraskovsky
Journal:  J Med Microbiol       Date:  2012-03-22       Impact factor: 2.472

4.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

5.  Expression, purification and refolding of a self-assembling protein nanoparticle (SAPN) malaria vaccine.

Authors:  Qin Guo; Debleena Dasgupta; Tais A P F Doll; Peter Burkhard; David E Lanar
Journal:  Methods       Date:  2013-03-30       Impact factor: 3.608

6.  Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.

Authors:  Justen H Passwell; Shai Ashkenazi; Efrat Harlev; Dan Miron; Reut Ramon; Nahid Farzam; Liat Lerner-Geva; Yonit Levi; Chiayung Chu; Joseph Shiloach; John B Robbins; Rachel Schneerson
Journal:  Pediatr Infect Dis J       Date:  2003-08       Impact factor: 2.129

7.  Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.

Authors:  Feng Qian; Kelly M Rausch; Olga Muratova; Hong Zhou; Guanhong Song; Ababacar Diouf; Lynn Lambert; David L Narum; Yimin Wu; Allan Saul; Louis H Miller; Carole A Long; Gregory E D Mullen
Journal:  Vaccine       Date:  2008-03-27       Impact factor: 3.641

Review 8.  Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.

Authors:  Stanley L Hem; Harm Hogenesch
Journal:  Expert Rev Vaccines       Date:  2007-10       Impact factor: 5.217

9.  Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

Authors:  Yimin Wu; Ruth D Ellis; Donna Shaffer; Erica Fontes; Elissa M Malkin; Siddhartha Mahanty; Michael P Fay; David Narum; Kelly Rausch; Aaron P Miles; Joan Aebig; Andrew Orcutt; Olga Muratova; Guanhong Song; Lynn Lambert; Daming Zhu; Kazutoyo Miura; Carole Long; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

10.  Single-dose microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting functional antibody response.

Authors:  R R Dinglasan; J S Armistead; J F Nyland; X Jiang; H Q Mao
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

View more
  14 in total

Review 1.  An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives.

Authors:  Alessio Facciolà; Giuseppa Visalli; Antonio Laganà; Angela Di Pietro
Journal:  Vaccines (Basel)       Date:  2022-05-22

2.  Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant Pfs25, a Leading Transmission-Blocking Vaccine Candidate.

Authors:  Elizabeth M Parzych; Kazutoyo Miura; Aarti Ramanathan; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

Review 3.  Protein-based antigen presentation platforms for nanoparticle vaccines.

Authors:  Brian Nguyen; Niraj H Tolia
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

4.  Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium.

Authors:  Camila Henriques Coelho; Justin Yai Alamou Doritchamou; Irfan Zaidi; Patrick E Duffy
Journal:  NPJ Vaccines       Date:  2017-11-30       Impact factor: 7.344

Review 5.  Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications.

Authors:  Young Hun Chung; Hui Cai; Nicole F Steinmetz
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

6.  Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models.

Authors:  Marco Tamborrini; Julia Hauser; Anja Schäfer; Mario Amacker; Paola Favuzza; Kwak Kyungtak; Sylvain Fleury; Gerd Pluschke
Journal:  NPJ Vaccines       Date:  2020-01-31       Impact factor: 7.344

7.  Bacterial superglue enables easy development of efficient virus-like particle based vaccines.

Authors:  Susan Thrane; Christoph M Janitzek; Sungwa Matondo; Mafalda Resende; Tobias Gustavsson; Willem Adriaan de Jongh; Stine Clemmensen; Will Roeffen; Marga van de Vegte-Bolmer; Geert Jan van Gemert; Robert Sauerwein; John T Schiller; Morten A Nielsen; Thor G Theander; Ali Salanti; Adam F Sander
Journal:  J Nanobiotechnology       Date:  2016-04-27       Impact factor: 10.435

8.  Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag'.

Authors:  Jing Jin; Kathryn A Hjerrild; Sarah E Silk; Rebecca E Brown; Geneviève M Labbé; Jennifer M Marshall; Katherine E Wright; Sandra Bezemer; Stine B Clemmensen; Sumi Biswas; Yuanyuan Li; Aadil El-Turabi; Alexander D Douglas; Pim Hermans; Frank J Detmers; Willem A de Jongh; Matthew K Higgins; Rebecca Ashfield; Simon J Draper
Journal:  Int J Parasitol       Date:  2017-01-30       Impact factor: 3.981

9.  Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells.

Authors:  Jing Jin; Richard D Tarrant; Emma J Bolam; Philip Angell-Manning; Max Soegaard; David J Pattinson; Pawan Dulal; Sarah E Silk; Jennifer M Marshall; Rebecca A Dabbs; Fay L Nugent; Jordan R Barrett; Kathryn A Hjerrild; Lars Poulsen; Thomas Jørgensen; Tanja Brenner; Ioana N Baleanu; Helena M Parracho; Abdessamad Tahiri-Alaoui; Gary Whale; Sarah Moyle; Ruth O Payne; Angela M Minassian; Matthew K Higgins; Frank J Detmers; Alison M Lawrie; Alexander D Douglas; Robert Smith; Willem A de Jongh; Eleanor Berrie; Rebecca Ashfield; Simon J Draper
Journal:  NPJ Vaccines       Date:  2018-08-17       Impact factor: 7.344

Review 10.  Synthetic biology for bioengineering virus-like particle vaccines.

Authors:  Hayley K Charlton Hume; João Vidigal; Manuel J T Carrondo; Anton P J Middelberg; António Roldão; Linda H L Lua
Journal:  Biotechnol Bioeng       Date:  2018-12-31       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.